These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 25791142)

  • 61. How resistant is 'treatment-resistant' obsessive-compulsive disorder in youth?
    Krebs G; Isomura K; Lang K; Jassi A; Heyman I; Diamond H; Advani J; Turner C; Mataix-Cols D
    Br J Clin Psychol; 2015 Mar; 54(1):63-75. PubMed ID: 25130442
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
    Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
    Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Pharmacological treatment of children and adolescents with OCD].
    Thomsen H
    Ugeskr Laeger; 2001 Jul; 163(27):3763-8. PubMed ID: 11466982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II.
    Conelea CA; Selles RR; Benito KG; Walther MM; Machan JT; Garcia AM; Sapyta J; Morris S; Franklin M; Freeman JB
    J Psychiatr Res; 2017 Sep; 92():94-100. PubMed ID: 28412602
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacological treatment of obsessive-compulsive disorder.
    Simpson HB
    Curr Top Behav Neurosci; 2010; 2():527-43. PubMed ID: 21309125
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intelligence quotient level and treatment of obsessive-compulsive disorders: Meta-analyses.
    Hu L; Hao Y; Liu S; Kang H; Qin L; Zeng Z; Abdelrahim MEA; Tan Y
    Med Hypotheses; 2020 Nov; 144():109995. PubMed ID: 32563973
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
    BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessment and medication management of paediatric obsessive-compulsive disorder.
    Stewart SE; Hezel D; Stachon AC
    Drugs; 2012 May; 72(7):881-93. PubMed ID: 22564131
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An overview of the pharmacological options for pediatric obsessive-compulsive disorder.
    Marazziti D; Pozza A
    Expert Opin Pharmacother; 2022 Nov; 23(16):1793-1800. PubMed ID: 36310087
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade].
    Prazeres AM; Souza WF; Fontenelle LF
    Braz J Psychiatry; 2007 Sep; 29(3):262-70. PubMed ID: 17713699
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder.
    Umehara H; Numata S; Tajima A; Nishi A; Nakataki M; Imoto I; Sumitani S; Ohmori T
    PLoS One; 2016; 11(6):e0157232. PubMed ID: 27281126
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Commonly asked questions in the treatment of obsessive-compulsive disorder.
    Arumugham SS; Reddy YC
    Expert Rev Neurother; 2014 Feb; 14(2):151-63. PubMed ID: 24372473
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder.
    Goldstein RB; Storch EA; Lehmkuhl H; Geffken GR; Goodman WK; Murphy TK
    Depress Anxiety; 2009; 26(1):E23-5. PubMed ID: 19067320
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacotherapy for obsessive-compulsive disorder.
    Greist JH; Jefferson JW
    Br J Psychiatry Suppl; 1998; (35):64-70. PubMed ID: 9829028
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.